Switch to:

Mirati Therapeutics Current Ratio

: 13.15 (As of Sep. 2019)
View and export this data going back to 2013. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Mirati Therapeutics's current ratio for the quarter that ended in Sep. 2019 was 13.15.

Mirati Therapeutics has a current ratio of 13.15. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

NAS:MRTX' s Current Ratio Range Over the Past 10 Years
Min: 0.41   Max: 17.57
Current: 13.15

0.41
17.57

During the past 13 years, Mirati Therapeutics's highest Current Ratio was 17.57. The lowest was 0.41. And the median was 7.44.

NAS:MRTX's Current Ratio is ranked higher than
85% of the 1180 Companies
in the Biotechnology industry.

( Industry Median: 4.42 vs. NAS:MRTX: 13.15 )

Mirati Therapeutics Current Ratio Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Mirati Therapeutics Annual Data
Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.05 12.80 3.97 11.42 8.67

Mirati Therapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.22 8.67 12.20 17.57 13.15

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Mirati Therapeutics Current Ratio Distribution

* The bar in red indicates where Mirati Therapeutics's Current Ratio falls into.



Mirati Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Mirati Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2018

Current Ratio (A: Dec. 2018 )=Total Current Assets (A: Dec. 2018 )/Total Current Liabilities (A: Dec. 2018 )
=226.66/26.146
=8.67

Mirati Therapeutics's Current Ratio for the quarter that ended in Sep. 2019 is calculated as

Current Ratio (Q: Sep. 2019 )=Total Current Assets (Q: Sep. 2019 )/Total Current Liabilities (Q: Sep. 2019 )
=464.648/35.336
=13.15

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Mirati Therapeutics  (NAS:MRTX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Mirati Therapeutics Current Ratio Related Terms


Mirati Therapeutics Current Ratio Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)